Product Details

An ideal system for younger patients. A unique combination of effective ingredients provides early intervention for loss of radiance and resilient feel; the appearance of minimal fine lines and wrinkles; dull complexion and uneven texture; and dry skin.

Kit Includes:

Exfoliating Cleanser

Retinol 0.5%

HydraFactor® Broad Spectrum SPF 30

Watch how the Obagi360 System can help preserve and protect youthful-looking skin.

Exfoliating Cleanser

Works to help clear dull, dry skin that can lead to clogged pores and uneven skin texture. Cleanser works mechanically and chemically to help reveal a soft, smooth, and radiant complexion.

Key Ingredient:
Linked papain

Retinol 0.5%

This entrapped form of retinol is gradually released, improving complexion, and smoothing the appearance of uneven skin texture for clearer-looking skin with minimal irritation.1,2

Obagi360® System

An ideal system for younger patients. A unique combination of effective ingredients provides early intervention for loss of radiance and resilient feel; the appearance of minimal fine lines and wrinkles; dull complexion and uneven texture; and dry skin.

Kit Includes:

Exfoliating Cleanser

Retinol 0.5%

HydraFactor® Broad Spectrum SPF 30

Watch how the Obagi360 System can help preserve and protect youthful-looking skin.

How It Works

Next-generation Skin Care for the Next Generation

The Obagi360 System is a complete approach to help protect and preserve youthful-looking skin. Uniquely formulated to address the facial skin care needs of people in their 20s and 30s, Obagi360 provides a foundation for a lifetime of radiant, healthy-looking skin.

Obagi360 can help you proactively address:

Dull, uneven skin texture and complexion

Appearance of minimal fine lines and wrinkles

Visible pores

Dry skin

Loss of skin radiance and resilience

A System of 3 Multifunctional Products That Offer 6 Outstanding Benefits

Cleanse

Exfoliate

Moisturize

Protect

Prevent

Perfect

Real Results

Improve Younger Skin Today and Prepare It for Tomorrow

See how the Obagi360 System helps provide notable improvements in the appearance of photoaging for younger-looking skin.*

Obagi360 Before & After1,†

BEFORE

WEEK 12

Obagi360 Before & After1,†

BEFORE

WEEK 12

*Photos have not been retouched. Results may vary. This product is not for the treatment of acne.†Study results for daily application of the Obagi360 System in a 12-week study; N=40.

Decrease in the Appearance of Common Skin Concerns

Notable improvements in the appearance of photoaging1,†,‡

Each sign of photoaging was assessed subjectively by the investigator on a seven-point
scale (0-6) at each timepoint; data represent reduction of the mean from the baseline for each sign.

Patients reported a decrease in breakouts, sallowness, and pore visibility by week 41,†,‡

At week 4, a majority of patients saw improvement in hyperpigmentation, skin texture, and the appearance of photodamage1,†,‡

High Patient Satisfaction

At week 4, patients were pleased with the system products1,†:

89% of patients would recommend the products to a friend

81% of patients were satisfied with the overall results of the products

At week 8, patients observed improvements in their appearance1,†:

88% of patients saw an improvement in their skin within the first week of use1,†

†Study results for daily application of the Obagi360 System in a 12-week study; N=40.‡Statistically significant improvement.

Consumer Satisfaction

Consumers are pleased with HydraFactor Broad Spectrum SPF 30.

In a separate survey, users began to see improvements within 3 weeks with HydraFactor2,§

78% reported skin felt moisturized throughout the day

78% reported skin felt protected all day

§Based on a consumer survey of 36 responders.

References: 1. Bruce S, Investigator. An open-label study to evaluate the anti-aging effects of three months of treatment using the Obagi360 System in subjects with photodamage: final analysis. Protocol OMP360-01; April 2014. Obagi Cosmeceuticals LLC. Data on file. 2. Consumer satisfaction survey, HydraFactor. Obagi Cosmeceuticals LLC. Data on file.

Sign up to receive exclusive emails for first-look access to new Obagi products, expert skin care tips and advice, special promotions, and more!

All fields required

First Name *

Email *

Are you a U.S. Resident? *

Yes

No

Zip Code *

Obagi will never sell, rent, or share your personal information with any third parties for marketing purposes without your express permission. By submitting your information, you confirm you have read and agree with the terms of our Privacy Policy.

Stay Connected With Obagi

Obagi Premier Points®

Earn points every time you purchase participating Obagi products from your physician. Join today and redeem accumulated points for free Obagi products in the future. Terms and conditions apply. Download the app to see full terms and conditions.

Obagi Systems and Products are physician-dispensed and should be used only under the guidance of your skin care physician. Please be advised that certain products have limited distribution and may not be available in your area. Please contact your Obagi skin care physician for more information.

Important Safety Information for Obagi Nu-Derm Clear and Blender®

(contains 4% hydroquinone)

CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.